Vaccine Candidate Shows Robust Immune Response Against the Aβ40 Peptide in Early-Stage Alzheimer's Patients

Araclon Biotech recently announced encouraging final results from its Phase 2 clinical trial of ABvac40, an active vaccine against the Aβ40 peptide, for treating patients with early-stage Alzheimer's disease (AD).

The results show that ABvac40 had a favorable safety profile, elicited a robust immune response against Aβ40, and demonstrated some potential cognitive benefits in early-stage AD patients.

The vaccine candidate met the primary endpoints and showed differences between the vaccine- and placebo-treated groups in some secondary exploratory endpoints.

ABvac40 is uniquely designed to target the C-terminal end of the Aβ40 peptide.

Thus, it is believed to prevent harmful reactions and avoid immune triggers responsible for meningoencephalitis, a complication observed in earlier AD vaccines.

Emerging research suggests that Αβ40 plays a role in cerebral amyloid angiopathy, a highly prevalent condition among the growing number of AD patients.

Notably, although the clinical trial was not powered for finding efficacy on neuropsychological scales, the ABvac40-treated group exhibited as much as a 38% reduction in disease progression, as reflected by the Mini-Mental State Examination score, suggesting ABvac40's potential efficacy in addressing the cognitive decline associated with AD.

Other neuropsychological tests, such as the Repeatable Battery for the Assessment of Neuropsychological Status and the Trial Making Test, showed favorable results on ABvac40 compared to the placebo group.

Global or functional scales did not show differences between the ABvac40 and placebo groups. In addition, volumetric magnetic resonance imaging showed a lesser increase in whole-brain atrophy in the ABvac40 group compared to the placebo group.

"We are pleased to report final positive results from the Phase 2 study of ABvac40, including a robust immune response with some significant reduction in disease progression, all with a favorable safety profile," said Jose Terencio, Ph.D., Araclon chief executive officer and vice president of Grifols Innovation and New Technologies, in a press release on October 25, 2023.

"Previous vaccines in development for AD faced setbacks due to harmful meningoencephalitis side effects."

"The results reported for ABvac40 to date validate its clinical potential, positioning it as a promising therapeutic candidate for early AD treatment. We look forward to evaluating the next steps for this program."

As of October 27, 2023, the U.S. FDA has not approved a vaccine targeting AD.